TLSI
TriSalus Life Sciences, Inc. NASDAQ Listed Feb 8, 2021$4.20
Pre-mkt
$3.99
-5.00%
Mkt Cap $159.2M
52w Low $2.52
33.7% of range
52w High $7.50
50d MA $3.90
200d MA $4.84
P/E (TTM)
-3.0x
EV/EBITDA
—
P/B
—
Debt/Equity
-1.0x
ROE
115.9%
P/FCF
-8.4x
RSI (14)
61.10
ATR (14)
$0.35
Beta
0.54
50d MA
$3.90
200d MA
$4.84
Avg Volume
676.2K
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
6272 West 91st Avenue · Westminster, CO 80031 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | AMC | -0.16 | -0.33 | -106.2% | 4.56 | -21.1% | -41.4% | -5.6% | +6.3% | +13.1% | +4.0% | — |
| Mar 5, 2026 | AMC | -0.13 | -0.12 | +7.7% | 4.77 | -1.5% | -6.3% | +3.4% | -7.8% | -2.3% | -1.4% | — |
| Nov 13, 2025 | AMC | -0.17 | -0.96 | -464.7% | 4.39 | -6.8% | +3.9% | -1.8% | +2.7% | -0.4% | +8.3% | — |
| Aug 12, 2025 | AMC | -0.22 | -0.27 | -22.7% | 3.65 | +3.8% | +8.2% | -1.8% | +17.3% | +6.8% | -4.3% | — |
| May 15, 2025 | AMC | -0.20 | -0.33 | -65.0% | 5.11 | +2.0% | +0.6% | +0.8% | +3.7% | +1.3% | -1.7% | — |
| Mar 27, 2025 | AMC | -0.35 | -0.35 | +0.0% | 5.50 | +1.3% | +2.2% | -1.8% | -0.4% | +0.5% | -5.6% | — |
| Nov 14, 2024 | AMC | -0.36 | -0.40 | -11.1% | 4.01 | -4.7% | -2.0% | -6.6% | +12.3% | -1.2% | +8.8% | — |
| Aug 14, 2024 | AMC | -0.49 | -0.21 | +57.1% | 5.85 | -2.9% | +0.7% | -2.4% | -0.9% | -2.1% | -0.7% | — |
| May 15, 2024 | AMC | -0.65 | -0.54 | +16.9% | 9.39 | +1.2% | +3.3% | +1.5% | +3.0% | -1.8% | -2.9% | — |
| Feb 27, 2024 | AMC | — | -1.34 | — | 9.22 | -0.8% | +2.6% | +0.8% | -2.3% | +5.5% | +0.6% | — |
| Nov 14, 2023 | AMC | — | -0.13 | — | 4.00 | +2.5% | -2.0% | +0.8% | -3.3% | -2.4% | +0.0% | — |
| Jun 30, 2023 | AMC | — | -0.53 | — | 10.48 | +0.2% | +0.2% | -0.2% | +0.3% | +0.0% | +0.0% | — |
| Mar 31, 2023 | AMC | — | -0.31 | — | 10.20 | +1.3% | +0.9% | +0.6% | +0.0% | -1.4% | +0.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.47 | $4.33 | -3.1% | +3.4% | -7.8% | -2.3% | -1.4% | -0.5% |
| Mar 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.77 | $4.70 | -1.5% | -6.3% | +3.4% | -7.8% | -2.3% | -1.4% |
| Dec 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.42 | $7.39 | -0.4% | -1.6% | -0.3% | +1.9% | +0.5% | -5.5% |
| Mar 28 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.50 | $5.57 | +1.3% | +2.2% | -1.8% | -0.4% | +0.5% | -5.6% |
| Jan 24 | Roth MKM | Maintains | Buy → Buy | — | $5.16 | $5.16 | +0.0% | +0.4% | +2.3% | -6.2% | -1.6% | +4.5% |
| Nov 15 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.01 | $3.82 | -4.7% | -2.0% | -6.6% | +12.3% | -1.2% | +8.8% |
| Jun 27 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.65 | $5.90 | +4.4% | +1.9% | -4.2% | -3.4% | -5.1% | +9.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 | Marshak RichardOff | Chief Commercial Officer | Sell | 543 | $2.67 | $1K | 125,101 | +2.86% | -0.93% |
| May 15, 2026 | Stansky Michael PDir | — | Buy | 200,000 | $2.50 | $500K | 399,698 | +3.96% | -1.23% |
| May 15, 2026 | Stansky Michael PDir | — | Buy | 410,000 | $2.50 | $1.0M | 1,240,722 | +3.96% | -1.23% |
| May 15, 2026 | Wahlstrom MatsDir | — | Buy | 60,000 | $2.53 | $152K | 147,555 | +3.96% | -1.23% |
| May 15, 2026 | Gordon Gary B.Dir | — | Buy | 10,000 | $2.46 | $25K | 72,510 | +3.96% | -1.23% |
| May 15, 2026 | Patience DavidOff | Chief Financial Officer | Buy | 7,100 | $2.43 | $17K | 275,757 | +3.96% | -1.23% |
| May 15, 2026 | Szela Mary TDir/Off | CEO and President | Buy | 39,682 | $2.59 | $103K | 1,065,215 | +3.96% | -1.23% |
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
DTSL and TLSI shareholders should monitor leadership continuity impacts, as executive transitions often affect strategic direction and stock performance depending on successor qualifications and market confidence.
Apr 7
8-K
TriSalus Life Sciences, Inc. -- 8-K Filing
TriSalus Life Sciences reported strong 2025 revenue growth of 53% to $45.2 million and raised $46 million through a public offering, positioning itself for continued expansion with 2026 guidance of $60-62 million.
Mar 5
8-K · 8.01
!! High
TriSalus Life Sciences, Inc. -- 8-K 8.01: Material Event / Announcement
TriSalus Life Sciences announced an offering on February 19, 2026, though specific terms remain undisclosed in this filing excerpt.
Feb 20
8-K · 5.02
!!! Very High
TriSalus Life Sciences, Inc. -- 8-K 5.02: Executive Change
TriSalus Life Sciences appointed Michael P. Stansky as director while Dr. Arjun JJ Desai resigned, effective February 4, 2026, signaling potential strategic shifts in board composition.
Feb 9
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Wasatch Advisors Lp | 1,437,960 | $6M | New | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 1,347,036 | $5M | New | Mar 2026 |
| 3 | Morgan Stanley | 730,510 | $5M | Added | Dec 2025 |
| 4 | Thompson Siegel & Walmsley Llc | 583,574 | $2M | New | Mar 2026 |
| 5 | Empire Financial Management Company, Llc | 300,275 | $1M | New | Mar 2026 |
| 6 | Northern Trust Corp | 221,473 | $886K | — | Mar 2026 |
| 7 | Bank Of America Corp /de/ | 201,719 | $807K | Added | Mar 2026 |
| 8 | Vanguard Portfolio Management Llc | 164,858 | $659K | New | Mar 2026 |
| 9 | Cwa Asset Management Group, Llc | 72,000 | $503K | — | Dec 2025 |
| 10 | Ubs Group Ag | 79,552 | $318K | Added | Mar 2026 |
| 11 | Sei Investments Co | 68,870 | $275K | New | Mar 2026 |
| 12 | Bank Of New York Mellon Corp | 65,804 | $263K | Added | Mar 2026 |
| 13 | Formula Growth Ltd | 50,000 | $200K | New | Mar 2026 |
| 14 | Nuveen, Llc | 36,550 | $146K | — | Mar 2026 |
| 15 | Highmark Wealth Management Llc | 33,300 | $133K | Added | Mar 2026 |
| 16 | Renaissance Technologies Llc | 30,900 | $124K | New | Mar 2026 |
| 17 | Man Group Plc | 23,358 | $93K | Added | Mar 2026 |
| 18 | Connecticut Wealth Management, Llc | 22,303 | $89K | — | Mar 2026 |
| 19 | Captrust Financial Advisors | 21,965 | $88K | New | Mar 2026 |
| 20 | Susquehanna International Group, Llp | 12,994 | $52K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$159.2M
Enterprise Value
$173.0M
P/E (TTM)
-2.98x
Forward P/E
—
PEG Ratio
-0.14x
P/B
—
P/S
3.55x
P/FCF
-8.41x
EV/EBITDA
—
Shares Out
37.9M
Financials (TTM)
Revenue
$44.9M
Net Income
-$27.3M
EBITDA
-$20.9M
Free Cash Flow
-$18.9M
Op Cash Flow
-$18.0M
EPS Basic
$-1.84
EPS Diluted
$-1.41
EPS Forward
$-0.38
Gross Margin
85.1%
Op Margin
-62.5%
Net Margin
-60.9%
Balance Sheet
Total Assets
$35.3M
Total Liab.
$69.2M
Total Equity
-$33.9M
Cash
$20.4M
LT Debt
$34.3M
Book Value/Sh
$-0.89
Debt/Equity
-1.02x
Current Ratio
2.80
Quick Ratio
2.54
Returns & Growth
ROE
115.9%
ROA
-111.0%
ROIC
-112.3%
Rev Growth YoY
+53.4%
EPS Growth YoY
-47.2%
Price Returns
2W
+35.3%
1M
-21.1%
3M
-32.6%
6M
-50.4%
12M
-31.8%
Technicals
52W High
$7.50
52W Low
$2.52
50d MA
$3.90
200d MA
$4.84
RSI (14)
61.10
ATR (14)
$0.35
Beta
0.54
Avg Volume
676K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$10.50
High
$11.00
Low
$10.00
Median
$10.50
Data updated apr 27, 2026 5:00am
· Source: financialmodelingprep.com